Stocklytics Platform
Asset logo for symbol DXCM
DexCom
DXCM
73
$110.50arrow_drop_down0.06%-$0.07
High Quality
S&P500

Performance History

Chart placeholder
Key Stats
Open$117.18
Prev. Close$116.07
EPS1.54
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$46.38B
PE Ratio75.74
LOWHIGH
Day Range114.22
117.27
52 Week Range74.75
142.00
Ratios
P/B Ratio25.38
Revenue$3.62B
Operating M. %10.98%
Earnings$541.50M
Earnings Growth %58.70%
EBITDA Margin %23.42%
ROE %28.54%
EPS1.54

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$902.23
Perf. (24h)
arrow_drop_up1.36%$12.12
Market Cap$840.04B
Price$484.53
Perf. (24h)
arrow_drop_down1.11%-$5.45
Market Cap$451.00B
Price$147.44
Perf. (24h)
arrow_drop_down1.12%-$1.67
Market Cap$357.99B
Price$132.89
Perf. (24h)
arrow_drop_down0.04%-$0.06
Market Cap$331.08B

About DexCom (DXCM)

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Kevin Ronald Sayer
Headquarters
San Diego
Employees
7500
Exchange
NASDAQ
add DexCom  to watchlist

Keep an eye on DexCom

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the 52-week high and low for DexCom (DXCM)?

For DexCom (DXCM), the 52-week high is $142, which is 28.51% from the current price. The 52-week low is $74.75, the current price is 47.83% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
What is DexCom 's (DXCM) price per share?

The current price per share for DexCom (DXCM) is $110.5. The stock has seen a price change of -$0.07 recently, indicating a -0.06% change. This reflects the stock's recent market performance and investor sentiment.

help
Is DexCom (DXCM) a growth stock?

DexCom (DXCM) has shown an average price growth of 0.41% over the past three years. It has received a score of 72 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying DexCom as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is DexCom (DXCM) stock price performance year to date (YTD)?

As of the latest data, DexCom (DXCM) has a year-to-date price change of -10.23%. Over the past month, the stock has experienced a price change of -13.24%. Over the last three months, the change has been -21.13%. Over the past six months, the figure is -10.56%. Looking at a longer horizon, the five-year price change stands at 199.34%.

help
Is DexCom (DXCM) a profitable company?

DexCom (DXCM) has a net income of $541.5M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 63.19% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 10.98% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $3.62B, with a revenue growth rate of 24.49%, providing insight into the company's sales performance and growth. The gross profit is $2.29B. Operating income is noted at $597.7M. Furthermore, the EBITDA is $995.6M.

help
What is the market capitalization of DexCom (DXCM)?

DexCom (DXCM) has a market capitalization of $46.39B. The average daily trading volume is 2.91M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level